Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces First Patient Dosed in China in a Potentially Registrational Study of Retifanlimab in Patients with Endometrial Cancer

SHANGHAI and SAN FRANCISCO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, today announced dosing of the...
October 28, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Upcoming Presentations in November Investor Conferences

SHANGHAI and SAN FRANCISCO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, today announced that...
October 09, 2020 08:48 ET | Source: Zai Lab Limited

Zai Lab Announces Full Exercise of the Over-allotment Option

SHANGHAI and SAN FRANCISCO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, announced full exercise of the...
October 06, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces First Patient Dosed in Greater China in the Global Phase 2/3 MAHOGANY Study of Margetuximab in Gastric and Gastroesophageal Junction Cancer

SHANGHAI and SAN FRANCISCO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, announced dosing of the first...
October 05, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces First Patient Dosed in China in a Global Phase 3 Study of Retifanlimab in Patients with NSCLC

SHANGHAI and SAN FRANCISCO, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, announced dosing of the first...
September 28, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces Closing of Hong Kong Secondary Listing

SHANGHAI and SAN FRANCISCO, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced...
September 22, 2020 07:53 ET | Source: Zai Lab Limited

Zai Lab Announces Pricing of Hong Kong Secondary Listing

SHANGHAI and SAN FRANCISCO, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced...
September 19, 2020 07:30 ET | Source: Zai Lab Limited

Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian cancer

The NORA study, presented as a late-breaker oral presentation at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress, demonstrates that niraparib maintenance treatment resulted in a...
September 16, 2020 07:15 ET | Source: Zai Lab Limited

Zai Lab Launches Hong Kong Secondary Listing

SHANGHAI and SAN FRANCISCO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB), an innovative commercial stage biopharmaceutical company, today announced...
September 10, 2020 07:30 ET | Source: Zai Lab Limited

Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China

- ZEJULA is the only PARP inhibitor approved as monotherapy for all-comer patients in the first-line and recurrent maintenance treatment settings regardless of biomarker status - ZEJULA was...